Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30754266 | 1.00 | MTNR1B (0.35) | MTNR1BMAPTMEN1GAAKMT2A | |
| SCHEMBL30949613 | 0.78 | HTR2A (0.43) | MTNR1BMAPTMEN1KMT2AMAOB | |
| SCHEMBL20741822 | 0.78 | HTR2A (0.43) | MTNR1BMAPTMEN1KMT2AMAOB | |
| SCHEMBL5546117 | 0.76 | MAOA (0.46) | MTNR1BMAOBMAOAPRKCIHTR2A | |
| SCHEMBL30973508 | 0.76 | MAOA (0.33) | MTNR1BMEN1KMT2AMAOBMAOA | |
| SCHEMBL30684141 | 0.76 | HTR2C (0.35) | MTNR1BMAPTGAAPRKCILMNA | |
| SCHEMBL20744138 | 0.76 | HTR2C (0.35) | MTNR1BMAPTGAAPRKCILMNA | |
| SCHEMBL16190013 | 0.76 | EED (0.34) | MTNR1BMAPTMAOBLMNAHTT | |
| SCHEMBL31634038 | 0.76 | EED (0.34) | MTNR1BMAPTMAOBLMNAHTT | |
| SCHEMBL21834717 | 0.72 | MTNR1B (0.34) | MTNR1BMAOBMAOAMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735429-A1 | TRIAZINE DERIVATIVES AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-20260109689-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4347571-B1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | HOFFMANN LA ROCHE (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-20260015353-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4630417-A1 | NOVEL COMPOUNDS AS MODULATORS OF NLRP3 INHIBITION | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| US-12421209-B2 | Compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4615841-A1 | TRIAZINONE DERIVATIVES AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| US-20250276958-A1 | COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-09-04 | — | — | US | disclosed |
| EP-4609865-A2 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250197370-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022253936-A1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022238347-A1 | NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-11-17 | — | — | WO | disclosed |
| US-11014917-B2 | 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-25 | — | — | US | disclosed |
| US-20200291004-A1 | 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| US-10696662-B2 | 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-30 | — | — | US | disclosed |
| US-20190055226-A1 | 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-21 | — | — | US | disclosed |
| EP-2513092-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073114-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055226-A1 | 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS | SLC5A2, SLC5A1, SLC2A2 | MTNR1B 1538/4885MAPT 1022/4885MEN1 4604/4885 |
| US-10696662-B2 | 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | MTNR1B 1538/4885MAPT 1022/4885MEN1 4604/4885 |
| US-12421209-B2 | Compounds | C5, RB1, RPS4X | MTNR1B 435/4885MAPT 3069/4885MEN1 160/4885 |
| US-20260015353-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NOD2 | MTNR1B 740/4885MAPT 3487/4885MEN1 4144/4885 |
| US-20200291004-A1 | 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS | SLC5A2, SLC5A1, SLC2A2 | MTNR1B 1551/4885MAPT 840/4885MEN1 4568/4885 |
| US-20250276958-A1 | COMPOUNDS | C5, RB1, RPS4X | MTNR1B 435/4885MAPT 3069/4885MEN1 160/4885 |
| US-20250197370-A1 | NOVEL COMPOUNDS | RB1, CDK11B, RPS4X | MTNR1B 388/4885MAPT 3588/4885MEN1 605/4885 |
| US-11014917-B2 | 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | MTNR1B 1551/4885MAPT 840/4885MEN1 4568/4885 |
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RRM2B, POLR2A, RRM2 | MTNR1B 560/4885MAPT 4459/4885MEN1 4751/4885 |
| US-20260109689-A1 | NOVEL COMPOUNDS | NOD1, NLRP3, NLRP1 | MTNR1B 1224/4885MAPT 779/4885MEN1 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.